Deerfield Management

Deerfield Management is a New York-based investment firm established in 1994 that focuses on healthcare. It operates across investment, information, and philanthropy to support the healthcare ecosystem. The firm provides private and public investments and offers long-term, structured capital to both public and private healthcare companies. Its portfolio spans life sciences, medical devices, diagnostics, digital health, and health services. As an investment adviser, it seeks opportunities in healthcare products and services and aims to accelerate innovation by combining capital with industry insight.

Steve Anastos

Principal

Sumner Anderson

Partner

Konstantinos Aprilakis

Partner

Talia Askowitz

Associate

Lawrence Atinsky JD

Partner

Michael Bergen

Principal

Nicholas Bishop

Partner

Brian Bizoza

Partner

Alexis Cazé

Partner and Co-COO

Alexis Cazé

Partner

Wenxi Chen

Analyst

Brian Chow

Principal

Andrew ElBardissi

Partner

James Flynn

Managing Partner

Jordan Fogel

Principal

Jason Fuller

Partner

Howard Furst

Partner

Bharath Ganesan

Principal

Bharath Ganesan

Principal

Adam Greene

Partner

Adam Grossman

Partner

Julian Harris

Partner

Jackson Harvey

Analyst

Leslie Henshaw

Partner

Steven Hochberg

Partner

Michael Hurley

Principal, Medical Technologies team

Jonathan Isler

Partner and CFO, Funds

Terence Karnal

Partner

Avi Kometz

Partner

Abraham Kometz

Partner

Timothy Leahy

Partner, Healthcare Services Team

Jonathan Leff

Partner

Gilan Megeed

Principal

Gilan Megeed

Principal

Vincent Mellet

Partner

Vince Mellet

Partner

Narendra Nayak

Partner

David Neustaedter Ph.D

Venture Partner

Elliot Press JD

Partner

Jonathan Ramos

Principal

Veranika Razhkova

Analyst

Bryan Sendrowski

Partner and Co-CFO

William Slattery

Partner, Therapeutics Team

Alison Stamas

Associate

Peter Steelman

Partner

Elise Wang

Partner

Cameron Wheeler

Partner

Crystal Wright

Associate

Eddie Yang

Analyst

Brian Chow Ph.D

Principal

334 past transactions

Ascertain

Series A in 2025
Ascertain is a collaborative venture between Northwell Health and Aegis Ventures, aimed at transforming healthcare through innovative company creation. This organization focuses on systematically developing, launching, and commercializing healthcare AI companies, utilizing a comprehensive platform that integrates medical, technological, data, and business resources. By addressing critical issues related to quality, equity, and cost in healthcare, Ascertain seeks to improve patient care and experience. The organization is dedicated to placing patient needs at the forefront of its business models and technology solutions, ultimately striving to enhance long-term health outcomes and advance the overall quality of care.

The Oncology Institute of Hope and Innovation

Post in 2025
The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

BiomX

Post in 2025
BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Achilles Internationl

Grant in 2025
Achilles International enables people with all types of disabilities to participate in running events to promote personal achievement.

Singular Genomics

Acquisition in 2024
Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Pleno

Series B in 2024
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Intus Care

Funding Round in 2024
Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

Lomond Therapeutics

Venture Round in 2024
Lomond Therapeutics is a pharmaceutical company specializing in the discovery and development of small molecule inhibitors targeting escape variants in hematologic malignancies.

Nema Health

Series A in 2024
Nema Health operates an online trauma care platform that delivers cognitive processing therapy and other PTSD treatments through a virtual care center. The service enables individuals with post-traumatic stress disorder and related stress disorders to receive therapy from home, administered by PTSD-trained therapists. The platform focuses on comprehensive, long-lasting relief through remote care, combining professional psychotherapy with convenient, privacy-conscious access to treatment.

Petfolk

Series C in 2024
Petfolk revolutionizes veterinary care by blending in-person visits with virtual consultations, ensuring high-quality and accessible care for pets and their owners. The company's approach emphasizes compassionate veterinarians and advanced technology to bridge the communication gap between pet owners and their vets. Petfolk offers a comprehensive range of services, from scheduled on-site care to virtual visits, fostering stronger bonds between pet parents and the veterinary professionals who serve them.

Pairwise Plants

Series C in 2024
Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.

SpectraWAVE

Series B in 2024
SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

Day One Biopharmaceuticals

Post in 2024
Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers across all ages, with an initial emphasis on pediatric patients. The company aims to bring effective cancer treatments to families by advancing therapies that can benefit both children and adults, prioritizing programs that can progress to the market rapidly. Day One pursues licensing or acquisition of promising products from research institutions and industry partners to expand its pipeline. Its lead candidate, DAY101, is an oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target cancers driven by the RAF signaling pathway. By applying insights from childhood cancer biology, the company seeks to address unmet needs in oncology and broaden access to precision therapies.

Elion Therapeutics

Series B in 2024
Elion Therapeutics is a biotechnology company dedicated to developing innovative treatments for life-threatening systemic fungal infections. The company focuses on enhancing the efficacy of Amphotericin B, a well-known antifungal drug, while ensuring that its formulations remain non-toxic to mammalian cells. By leveraging mechanistic insights, Elion aims to optimize natural compounds to create a broad spectrum of safe and effective antifungal therapies. Through its clinical research and development services, Elion Therapeutics is committed to addressing the urgent medical needs posed by invasive fungal infections.

Mereo Biopharma

Post in 2024
Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

R3 Vascular

Series B in 2024
R3 Vascular develops bioresorbable scaffold technology coated with sirolimus for treating peripheral arterial disease. Its proprietary polymer and technologies create scaffolds that balance strength and flexibility, with a thin strut thickness of 98 microns.

BridgeBio Oncology Therapeutics

Venture Round in 2024
BridgeBio Oncology Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapeutics. It focuses on targeting RAS-dependent cancers, leveraging a profound understanding of RAS signaling biology to create drugs that selectively inhibit RAS-driven PI3K activation and a wide spectrum of KRAS mutants. The company aims to provide patients with tailored treatments that address both active and inactive cancer-driving states.

Lumeris

Venture Round in 2024
Lumeris is a company focused on transforming accountable care delivery by providing operational support, technology, and consulting services to health systems, payers, and providers. It offers a value-based care managed services platform that enhances clinical and financial outcomes through guidance and advanced risk management capabilities. By collaborating with healthcare organizations across the country, Lumeris helps them design, build, and optimize accountable care models aimed at improving quality, reducing costs, and enhancing patient and physician satisfaction. The company's innovative solutions are designed to yield better health outcomes for patients while addressing the challenges associated with chronic diseases, ultimately supporting the overarching goals of improved quality, cost efficiency, and satisfaction in the healthcare system.

Relation Therapeutics

Seed Round in 2024
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

Vesta Healthcare

Venture Round in 2024
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

BiomX

Post in 2024
BiomX develops bacteriophage-based therapies targeting bacteria linked to skin conditions and chronic diseases such as inflammatory bowel disease, liver disorders, and cancer. It collaborates with renowned institutions for research and development, aiming to create innovative microbiome therapeutics.

Frontier Medicines

Series C in 2024
Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

MMI

Series C in 2024
MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Reprieve Cardiovascular

Series A in 2024
Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, established in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure. Its flagship product, the Reprieve technology, offers a solution for clinicians to precisely control the fluid volume in patients suffering from acute decompensated heart failure (ADHF). This ability to manage fluid levels is essential for improving cardiac care and assisting in the decongestion process for these patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

enGene

Post in 2024
EnGene specializes in developing a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. Its core technology enables localized delivery of immune-modulating proteins to intestinal mucosa using non-integrating biopolymer-based nucleotides, impacting diseases affecting mucosal tissues and facilitating systemic protein release.

Cogent Biosciences

Post in 2024
Cogent Biosciences is a biotechnology company dedicated to developing precision therapies for genetically defined diseases, aiming to treat the underlying causes and improve patient lives. The company employs proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body's immune system against cancer. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor designed to inhibit specific mutations in KIT exon 17, which are associated with Systemic Mastocytosis and advanced gastrointestinal stromal tumors (GIST).

Cohere Health

Series C in 2024
Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

Kura Oncology

Post in 2024
Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer patients. Its pipeline comprises small molecule drug candidates targeting specific cancer signaling pathways, with a focus on solid tumors and hematologic malignancies.

CalciMedica

Post in 2024
CalciMedica is a biopharmaceutical company focused on developing therapeutics for inflammatory and autoimmune disorders. It specializes in discovering and developing small molecule drugs that target calcium release-activated calcium channels.

Solid Biosciences

Post in 2024
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease primarily affecting boys. The company's lead product candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in patients' muscles. In addition to SGT-001, Solid Biosciences is advancing the Anti-LTBP4 program, which involves a monoclonal antibody designed to reduce fibrosis and inflammation by targeting the LTBP4 protein. The company also develops biomarkers and sensors, as well as the Solid Suit program, which focuses on creating wearable assistive devices with functional and therapeutic benefits. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to enhance gene therapy development for DMD. With no current cure for DMD, the company aims to provide innovative solutions for a condition that affects an estimated 10,000 to 15,000 cases in the United States.

Adela

Series A in 2023
Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Actio Biosciences

Series A in 2023
Actio Biosciences specializes in developing precision medicines tailored to homogeneous rare patient populations. Its pipeline focuses on creating new drugs designed to enhance clinical success rates and ultimately deliver treatments to all patients in need, including those with challenging-to-cure illnesses.

Valneva

Post in 2023
Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

Octave

Series B in 2023
Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Presidio Medical

Series C in 2023
Presidio Medical is a clinical-stage medical device company based in South San Francisco, California. It develops a neuromodulation platform intended to treat chronic pain by modulating neural activity and addressing disorders of neuronal function. The company pursues bioelectronic medicine to create a new class of therapeutic devices, combining biotechnology and neuromodulation to provide remedies for neural disorders.

Adaptive Phage Therapeutics

Series B in 2023
Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Bitterroot Bio

Series A in 2023
Bitterroot Bio specializes in developing innovative therapies for cardiovascular disease by harnessing the power of immunotherapy.

Ray Therapeutics

Series A in 2023
Ray Therapeutics develops optogenetic gene therapies to restore vision in patients with blinding retinal diseases. The company designs therapies that use bioengineered light-sensitive proteins delivered to targeted retinal cells via intravitreal injections, with the goal of improving visual function across various forms of retinal blindness and inherited retinal diseases. By combining gene delivery with optogenetic control, Ray Therapeutics aims to provide durable, long-term benefits from a single treatment, addressing diseases that lead to severe retinal degeneration. The company focuses on advancing research and development in this niche field to enable patients with limited or no light perception to regain functional sight, supporting efforts to study rare retinal conditions and translate laboratory insights into potential clinical therapies.

Ascend Gene & Cell Therapies

Series A in 2023
Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Cortica

Series D in 2023
Cortica Inc. is a company dedicated to providing neurological therapies for children facing autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers tailored treatment programs that are informed by a comprehensive understanding of each child's neurobiology and developmental profile. The company operates multiple centers across California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village. Cortica's services encompass a wide range of assessments and therapies, including diagnoses for autism, ADHD, and developmental delays. Treatment options available include gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and various therapeutic interventions such as ABA therapy, parent coaching, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company provides these services through in-home, in-clinic, and telehealth modalities.

Epic Sciences

Series G in 2023
Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Abivax

Post in 2023
Abivax is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in autoimmune and inflammatory diseases. Its portfolio aims to address large unmet needs across autoimmune conditions, viral infections, and cancer, with obefazimod in Phase 3 trials for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease. The company relies on its drug development platforms to advance treatments that modulate the immune system and potentially extend benefits to other inflammatory indications.

IronMatt

Grant in 2023
IronMatt's mission is to build a network committed to providing assistance to reduce family hardship, and fund pediatric brain tumor research, and patient care.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages advanced protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By employing multiple therapeutic modalities, Perceive Biotherapeutics aims to provide medical professionals with effective solutions for preventing vision loss and enhancing patient outcomes in the field of ophthalmology.

FogPharma

Series D in 2022
FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Abeona Therapeutics

Post in 2022
Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing and delivering gene therapy-based treatments for severe and life-threatening rare genetic diseases. Its pipeline includes therapies for Sanfilippo syndrome types A and B, epidermolysis bullosa, Batten disease, cystic fibrosis, and genetic eye disorders.

Intus Care

Series A in 2022
Founded in 2018, Intus Care develops a platform that connects home care providers with patients. Its application uses machine learning to predict hospital readmissions and risks, enabling efficient tracking of care providers and high-risk patient identification.

COTA Healthcare

Series E in 2022
COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Sientra

Post in 2022
Sientra is a medical device company based in Santa Barbara, California, specializing in breast implant treatments for both augmentation and reconstruction. Founded by Hani Zeini, the company develops innovative implantable devices that cater to the needs of plastic surgeons. Sientra's product offerings include silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, focusing on providing elegant and intuitive options for cosmetic and reconstructive surgery. The company's commitment to quality and innovation positions it as a significant player in the surgical aesthetics market.

Pleno

Series A in 2022
Pleno is a biotechnology company based in San Diego, California, founded in 2017. The company specializes in accelerating disease diagnosis and treatment through its innovative multi-omic platform. This technology is designed for biological target detection in clinical testing and biomedical research, offering capabilities for monitoring minimal residual disease and early multi-cancer screening. Pleno's platform detects a wide range of analytical targets, including DNA, RNA, and protein biomarkers, with exceptional speed and precision. By utilizing advanced microfluidics, the company automates all aspects of sample preparation and analysis, thereby enhancing healthcare providers' access to diverse health monitoring technologies.

Larimar Therapeutics

Post in 2022
Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. Its lead compound, CTI-1601, is currently in Phase 1 clinical trials as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.

Innervace

Series A in 2022
Founded in Philadelphia in 2018, Innervace is a regenerative therapy company focused on developing implantable tissue-engineered brain pathways for neurodegenerative disorders. Its lead product is a tissue-engineered nigrostriatal pathway designed to mimic the lost pathway in Parkinson's patients, providing potential disease-modifying therapies.

SpringWorks Therapeutics

Post in 2022
SpringWorks Therapeutics is a clinical-stage biopharmaceutical company applying precision medicine to develop medicines for severe rare diseases and cancer. It maintains a differentiated targeted oncology portfolio with lead candidates nirogacestat, a gamma secretase inhibitor, and mirdametinib, a MEK inhibitor, both in late-stage trials; the pipeline also includes BGB-3245, an oral inhibitor of activating BRAF mutations, in Phase I, and several combination programs. The company pursues collaborations with BeiGene, GlaxoSmithKline, and Allogene and has license agreements with Pfizer for nirogacestat and mirdametinib. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks aims to advance potentially registrational studies in rare tumor types and genetically defined cancers through partnerships that expand its portfolio and patient access.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Vicinitas Therapeutics

Series A in 2022
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

MMI

Series B in 2022
MMI S.r.l. is an Italian company that specializes in the manufacture and development of advanced micro instruments designed for surgical interventions. Founded in 2015 and based in Calci, Italy, MMI focuses on creating wristed micro instruments and their associated fabrication processes. The company also offers a proprietary robotic platform that enhances the capabilities of these instruments, facilitating complex reconstruction procedures following traumatic injuries and tumor removals in areas such as the breast, head, and bones. MMI aims to support surgeons globally by providing innovative tools that improve surgical outcomes while also reducing costs for patients and healthcare systems.

Humanity Health

Series A in 2022
Humanity Health is a platform dedicated to advancing the careers of underrepresented leaders in healthcare and life sciences. By leveraging best-in-class technology and a personalized service approach, the company creates career-accelerating opportunities for women and people of color. It aids employer partners in identifying, engaging, and recruiting diverse healthcare talent, thus fostering more inclusive hiring practices. A key component of Humanity Health is its Humanity Talent Network, a private membership network that amplifies and supports experienced leaders from underrepresented backgrounds. This network focuses on enhancing access to competitive executive positions, board roles, and entrepreneurial ventures, ultimately contributing to a more equitable landscape within the healthcare and life sciences sectors.

Insilico Medicine

Series D in 2022
Insilico Medicine, Inc. is a biotechnology company that leverages artificial intelligence (AI) to transform drug discovery, biomarker development, and aging research. Founded in 2014 and based in Baltimore, Maryland, the company has established itself as a pioneer in applying advanced AI techniques, such as generative adversarial networks and reinforcement learning, to create novel molecular structures for various diseases, including cancer and age-related conditions. Insilico Medicine operates an integrated platform that covers all stages of drug discovery, from initial research to clinical trial analysis. Its projects include Pharma.AI, which offers machine learning services to various sectors, and Young.AI, a platform focused on aging predictors. The company also pursues internal drug discovery initiatives targeting diseases like Alzheimer's and Parkinson's, and has partnered with Life Extension to produce nutraceutical products utilizing deep learning and bioinformatics. Additionally, Insilico Medicine provides consumer applications aimed at enhancing health and longevity.

Epic Sciences

Series F in 2022
Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

UTR Therapeutics

Pre Seed Round in 2022
UTR Therapeutics Inc is a biotechnology company focused on developing treatments for aggressive cancers driven by the overexpression of the c-MYC gene. The company, spun out from City University of New York and Harvard Medical School, specializes in researching and developing therapeutics that target and degrade specific gene transcripts involved in tumor progression. Their primary focus is on cancers like triple negative breast cancer, medulloblastoma, and osteosarcoma, aiming to provide clinicians with treatments that directly act on cancer-causing genetic expressions.

Acutus Medical

Post in 2022
Acutus Medical designs, manufactures, and markets tools for catheter-based ablation procedures to treat various cardiac arrhythmias worldwide. Its product portfolio includes access sheaths, transseptal crossing tools, diagnostic catheters, ablation catheters, mapping consoles, and supporting software.

Valneva

Post in 2022
Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

Apertura Gene Therapy

Series A in 2022
Apertura Gene Therapy focuses on advancing gene therapy treatments for severe diseases. It innovates by simultaneously engineering adeno-associated virus (AAV) capsids, regulatory elements, and payloads to overcome current limitations in gene therapy.

Aurion Biotechnologies

Venture Round in 2022
Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Vibliome

Series A in 2022
Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

ConcertoCare

Series B in 2022
ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

Hyperfine

Post in 2021
Hyperfine is a pioneering medical device company that developed Swoop®, the world's first FDA-cleared point-of-care MRI system. Designed to enhance patient access to critical care, Swoop produces high-quality images rapidly and at a lower cost than conventional MRIs, enabling clinicians to diagnose and treat patients swiftly in various clinical settings.

V-Wave

Series C in 2021
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.

The Oncology Institute of Hope and Innovation

Post in 2021
The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

Lark

Series D in 2021
Lark is a developer of a virtual platform focused on chronic disease prevention and management. Founded in 2011 by Julia Hu and Jeff Zira, the company is headquartered in Mountain View, California. Lark's platform leverages advanced artificial intelligence alongside human coaching and connected devices to offer real-time, personalized support and counseling. This approach aims to help users make healthier choices and effectively manage their chronic conditions. The company's programs, including those recognized by the CDC for diabetes prevention, wellness, diabetes care, and hypertension, serve approximately 1.5 million users. These initiatives have shown clinically validated improvements in health outcomes, as documented in multiple peer-reviewed journals and analyst reports.

DeepSight Technology

Series A in 2021
DeepSight Technology enhances diagnostic medical imaging by advancing ultrasound technology. It offers proprietary sensing technology and customizable systems, integrating with industry partners to provide clinicians with deeper insights for improved patient outcomes.

BioAtla

Post in 2021
BioAtla, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary platforms, Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!), to create highly selective and effective drugs. Its lead product candidate, BA3011, is a conditionally active biologic antibody-drug conjugate targeting soft tissue and bone sarcomas, non-small cell lung cancer, and other tumor types. Additionally, BioAtla is developing BA3021, aimed at non-small cell lung cancer and melanoma, as well as BA3071, which targets multiple cancers, including renal cell carcinoma and hepatocellular carcinoma. The company holds over 150 issued patents and applications, emphasizing its commitment to improving drug selectivity and safety while expanding the range of treatable cancers.

HilleVax

Venture Round in 2021
HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

ARS Pharmaceuticals

Series D in 2021
ARS Pharmaceuticals, Inc., established in 2015 and headquartered in San Diego, California, is a biopharmaceutical company focused on developing innovative treatments for severe allergic reactions. The company has created a novel intranasal epinephrine spray known as neffy, designed for the emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy utilizes a proprietary formulation that includes an absorption enhancer called Intravail, enabling it to deliver epinephrine effectively and rapidly through the nasal mucosa. This unique technology provides a convenient, reliable, and easy-to-use alternative for individuals at risk of life-threatening allergic reactions due to food, medications, or insect stings.

PepGen

Venture Round in 2021
PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Strata Oncology

Series C in 2021
Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

GeneDx

Post in 2021
GeneDx specializes in delivering personalized insights from genomic data to improve health outcomes. It combines extensive genetic expertise with advanced data science capabilities.

Frontier Medicines

Series B in 2021
Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Novocardia

Series A in 2021
Novocardia is dedicated to enhancing the delivery of cardiovascular care, aiming to support patients with heart and vascular diseases in achieving longer and healthier lives. The company operates a cardiovascular care delivery network that emphasizes improving the quality and value of care provided to patients. By fostering collaborative relationships with health plans and primary care partners, Novocardia facilitates the transition to value-based care. Its platform encompasses various capabilities, including the implementation of quality and process improvement initiatives and technology-enabled care delivery, thereby equipping cardiologists with the necessary tools to better serve their patients.

Adela

Series A in 2021
Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Talkspace

Post in 2021
Talkspace is an online therapy platform connecting users with licensed therapists, psychologists, and psychiatrists for mental health support. It offers unlimited messaging therapy, making professional help accessible and affordable.

Synthekine

Series B in 2021
Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

CareMax

Post in 2021
CareMax is a technology-enabled care platform focused on delivering value-based care and chronic disease management for seniors. The company operates a network of medical centers that provide a wide range of healthcare and social services. Additionally, CareMax has developed a proprietary software and services platform that offers data, analytics, and rules-based decision tools to assist physicians in their practice. This integrated approach aims to enhance the quality of care for seniors while managing their healthcare needs effectively across the United States.

Larimar Therapeutics

Post in 2021
Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. Its lead compound, CTI-1601, is currently in Phase 1 clinical trials as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.

ADC Therapeutics

Post in 2021
ADC Therapeutics is a clinical-stage biotechnology company focused on developing highly potent and targeted antibody-drug conjugates (ADCs) for treating hematological cancers and solid tumors. Its lead product, ZYNLONTA, is FDA-approved for relapsed or refractory large B-cell lymphoma.

Singular Genomics

Convertible Note in 2021
Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Adaptive Phage Therapeutics

Series B in 2021
Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Nuvalent

Series B in 2021
Nuvalent is a biotechnology company focused on developing targeted therapies for clinically proven kinase targets in cancer. Leveraging expertise in structure-based design, Nuvalent creates innovative small molecules with exquisite target selectivity to overcome resistance and minimize adverse events.

Jaguar Gene Therapy

Series B in 2021
Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Cohere Health

Series B in 2021
Founded in 2019 and based in Boston, Cohere Health is a healthcare technology company dedicated to enhancing efficiency and effectiveness within the healthcare system. It achieves this by leveraging technology to simplify processes, improve communication among stakeholders, and ultimately optimize patient outcomes.

GH Research

Series B in 2021
GH Research is a clinical-stage biopharmaceutical company focused on developing therapies for psychiatric and neurological disorders, with an emphasis on treatment-resistant depression. It is advancing novel and proprietary mebufotenin (5-MeO-DMT) therapies, including inhalable and intravenous product candidates, to provide transformative treatment options for patients who do not respond to existing therapies. The portfolio includes GH001, an inhalable mebufotenin candidate, and GH002, an intravenous candidate. The company concentrates its activities in research and development to create practice-changing solutions for depression.

Vesta Healthcare

Venture Round in 2021
Vesta Healthcare is a technology and clinical services organization based in New York, specializing in connecting caregivers to care teams through its innovative health care platform. The company offers 24/7 telehealth support aimed at caregivers and care recipients, particularly focusing on high-need, frail senior populations. Vesta partners with home care agencies, health plans, and healthcare providers to develop value-based population health programs that prioritize clinical quality and improved health outcomes. Founded in 2008 and originally known as Hometeam Technologies, Inc., Vesta Healthcare has established itself as a leader in enhancing caregiver insights and facilitating personalized engagement in the healthcare setting.

Crossover Health

Series D in 2021
Crossover Health designs and delivers workplace healthcare services for employers and employees, offering primary care and a broad range of ancillary and advanced services, including urgent and preventive care, chronic disease management, health risk assessment, health education, coaching, biometrics, physical therapy, chiropractic, acupuncture, care coordination, health analytics, and remote care. It operates as a primary care medical group that blends health management services with technology-enabled tools to create a comprehensive employee care experience. Founded in 2010 and based in California, Crossover Health serves client organizations through on-site and partner health centers across Silicon Valley and other U.S. locations, with a focus on improving access to care, enhancing member experience, and reducing healthcare costs for employers and their workforce.

Twill

Series D in 2021
Twill is a developer of a software-enabled healthcare platform focused on enhancing mental and physical wellness. The company offers a web and mobile-based technology that evaluates users' happiness through both subjective and objective assessments. In addition, Twill provides a variety of programs and games designed to promote healthier mindsets. This approach enables individuals, employers, and care delivery systems to effectively address issues such as stress, depression, anxiety, and social isolation, which are often associated with chronic illness. By integrating these tools, Twill aims to support users in achieving improved overall well-being.

Xeris Biopharma

Post in 2021
Xeris Biopharma is a specialty pharmaceutical company developing ready-to-use, liquid-stable injectables using its proprietary XeriSol and XeriJect formulation technologies. These platforms enable subcutaneous and intramuscular delivery of various drugs, offering advantages such as room temperature stability, reduced injection volume, and ease of use for patients and healthcare practitioners.

Jaguar Gene Therapy

Series A in 2021
Jaguar Gene Therapy is developing gene therapy treatments for severe genetic diseases. Its clinical-stage pipeline focuses on neurodevelopmental disorders, Type 1 galactosemia, and Type 1 diabetes.

Xilio Therapeutics

Series C in 2021
Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

SpectraWAVE

Series A in 2021
SpectraWAVE is a medical device company that develops intravascular optical imaging systems to diagnose and treat cardiovascular disease. Its technology integrates imaging and computation to help interventional cardiologists identify vulnerable plaques and guide coronary interventions, improving outcomes for patients with coronary artery disease. Headquartered in Waltham, Massachusetts, the company was founded in 2017.

Pairwise Plants

Series B in 2021
Pairwise Plants is an innovative agricultural company based in San Diego, California, focused on gene editing to enhance the quality of fruits and vegetables. Founded in 2017 by a team of experts in biotechnology and agriculture, Pairwise utilizes advanced techniques, including base editing and high-fidelity enzymes, which are licensed from renowned institutions such as Harvard and Massachusetts General Hospital. The company develops new varieties of crops, including leafy greens, berries, and stone fruits, in addition to working with traditional crops like corn, soybeans, wheat, cotton, and canola. By collaborating with food and agriculture organizations, Pairwise aims to create healthier and more sustainable produce, with initial products expected to be available in the coming years.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.